EGFR inhibitor monoclonal antibody

This page covers all EGFR inhibitor monoclonal antibody drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting EGFR (Epidermal Growth Factor Receptor).

Targets

EGFR (Epidermal Growth Factor Receptor)

Marketed (1)

• Nimotuzumab Injection · Biotech Pharmaceutical Co., Ltd. · Oncology
  Nimotuzumab is a humanized monoclonal antibody that blocks the epidermal growth factor receptor (EGFR) to inhibit tumor cell proliferation and survival.

Phase 3 pipeline (3)

• Nimotuzumab ( h-R3) · El Kendi Pharmaceuticals Manufacturing Company · Oncology
  Nimotuzumab is a monoclonal antibody that blocks the epidermal growth factor receptor (EGFR) to inhibit tumor cell proliferation and survival.
• RT plus Nimotuzumab · Sun Yat-sen University · Oncology
  Nimotuzumab is a monoclonal antibody that blocks epidermal growth factor receptor (EGFR) signaling, combined with radiotherapy (RT) to enhance tumor cell death in cancer treatment.
• Cetuximab injection · Shanghai Miracogen Inc. · Oncology
  Cetuximab is a monoclonal antibody that blocks the epidermal growth factor receptor (EGFR) on cancer cells, preventing growth signals and inducing cell death.